Search
Leukemia Clinical Trials
A listing of 49 Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 49
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Leukemia
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 49 active clinical trials seeking participants for Leukemia research studies. The states with the highest number of trials for Leukemia participants are California, New York, Illinois and Texas.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Recruiting
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS).
Phase 1 (Dose Escalation) will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1 of the study.
Phase 1b (Dose Expansion... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: University of California Los Angeles, Los Angeles, California +8 locations
Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
CIML NK Cells With Venetoclax for AML
Recruiting
The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML).
Names of the study therapies involved in this study are:
* Lymphodepleting therapy with Fludarabine and Cyclophosphamide prior to CIML NK cell infusion
* CIML NK (a cellular therapy)
* IL-2 (a recombinant, human... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Recruiting
To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control the disease.
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Recruiting
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Blood Cancer, Leukemia
Venetoclax Combined with Vyxeos (CPX-351) for Participants with Relapsed or Refractory Acute Leukemia
Recruiting
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
03/10/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Leukemia
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Recruiting
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy.
GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: City of Hope Medical Center, Duarte, California +5 locations
Conditions: COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Recruiting
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's Dementia (AD) and the hematological malignancies leading to HCT. There are shared mechanisms and interactions between AD and cancer-related cognitive decline (CRCD). Physical activity improves cogniti... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/03/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasm, Myelodysplastic Syndromes (MDS)
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/18/2025
Locations: City of Hope Phoenix, Goodyear, Arizona +253 locations
Conditions: Leukemia
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Recruiting
To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/13/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, HOX Gene
Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +24 locations
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Recruiting
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment. There is no standard treatment for the cancer at this time or the currently used treatments do not work completely in all cases like these. This is a gene transfer research study using special immune cells.
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Lymphoma, Myeloma, Leukemia
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Recruiting
The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +2 locations
Conditions: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
1 - 12 of 49